



Carroll, H. A., Templeman, I., Chen, Y-C., Edinburgh, R. M., Burch, E. K., Jewitt, J. T., Povey, G., Robinson, T. D., Dooley, W. L., Jones, R., Tsintzas, K., Gallo, W., Melander, O., Thompson, D., James, L. J., Johnson, L., & Betts, J. A. (2019). Effect of acute hypohydration on glycemic regulation in healthy adults: a randomized crossover trial. *Journal of Applied Physiology*, 126(2), 422-430.  
<https://doi.org/10.1152/jappphysiol.00771.2018>

Peer reviewed version

Link to published version (if available):  
[10.1152/jappphysiol.00771.2018](https://doi.org/10.1152/jappphysiol.00771.2018)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via APS at <https://www.physiology.org/doi/abs/10.1152/jappphysiol.00771.2018> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

# The effect of acute hypohydration on glycemic regulation in healthy adults: a randomized crossover trial

**Running title:** Effect of hydration status on glycemia

Harriet A. Carroll<sup>1</sup>, Iain Templeman<sup>1</sup>, Yung-Chih Chen<sup>1</sup>, Robert M. Edinburgh<sup>1</sup>, Elaine K. Burch<sup>1</sup>, Jake T. Jewitt<sup>1</sup>, Georgie Povey<sup>1</sup>, Timothy D. Robinson<sup>1</sup>, William L. Dooley<sup>1</sup>, Robert Jones<sup>2</sup>, Kostas Tsintzas<sup>2</sup>, Widet Gallo<sup>3</sup>, Olle Melander<sup>3</sup>, Dylan Thompson<sup>1</sup>, Lewis J. James<sup>4</sup>, Laura Johnson<sup>5</sup>, James A. Betts<sup>1</sup>

<sup>1</sup>Department for Health, University of Bath, UK

<sup>2</sup>School of Life Sciences, University of Nottingham, UK

<sup>3</sup>Department of Clinical Sciences, Lund University, Sweden

<sup>4</sup>School of Sport, Exercise and Health Sciences, Loughborough University, UK

<sup>5</sup>School for Policy Studies, University of Bristol, UK

**Corresponding author:** Harriet A. Carroll: Department for Health, University of Bath, BA2 7AY UK.; +441225385361; h.a.carroll@bath.ac.uk

**Author contributions:** Conception, HAC; design, HAC, DT, LJJ, LJ, JAB; conducted the experiment, HAC, IT, YCC, RME, EKB, JTJ, GP, TDR, WLD, JAB; data analysis and interpretation, HAC, IT, YCC, RJ, KT, WG, OM, LJJ, JAB

**Abbreviations:** ACTH, adrenocorticotrophic hormone; ANOVA, analysis of variance; AUC, area under the curve; AVP, arginine vasopressin; CI, confidence interval; CSMA, cross-sectional muscle area; EI, energy intake; HYPO, hypohydrated trial arm; iAUC, incremental area under the curve; OGTT, oral glucose tolerance test; pQCT, peripheral quantitative computer tomography; RE, rehydrated trial arm; SD, standard deviation; USG, urine specific gravity; VR, vasopressin receptor

**Trial registration:** Clinicaltrials.gov: NCT02841449  
Open Science Framework: osf.io/ptq7m

**Dataset available from:** <https://doi.org/10.15125/BATH-00547>

## 1 Abstract

2 The aim of this study was to investigate the acute effect of hydration status on glycemic  
 3 regulation in healthy adults and explore underlying mechanisms. In this randomized crossover  
 4 trial, 16 healthy adults (8 male) underwent an oral glucose tolerance test (OGTT) when  
 5 hypohydrated and rehydrated, after four days of pre-trial standardization. One day pre-OGTT,  
 6 participants were dehydrated for 1-h in a heat-tent with subsequent fluid restriction (HYPO)  
 7 or replacement (RE). The following day, an OGTT was performed with metabolic rate  
 8 measures and pre- and post-OGTT muscle biopsies. Peripheral quantitative computer  
 9 tomography thigh scans were taken pre- and post-intervention to infer changes in cell volume.  
 10 HYPO (but not RE) induced  $1.9 \pm 1.2\%$  body mass loss,  $2.9 \pm 2.7\%$  cell volume reduction, and  
 11 increased urinary hydration markers, serum osmolality, and plasma copeptin concentration  
 12 (all  $p \leq 0.007$ ). Fasted serum glucose (HYPO  $5.10 \pm 0.42 \text{ mmol} \cdot \text{l}^{-1}$ ; RE  $5.02 \pm 0.40 \text{ mmol} \cdot \text{l}^{-1}$ ;  
 13  $p = 0.327$ ) and insulin (HYPO  $27.1 \pm 9.7 \text{ pmol} \cdot \text{L}^{-1}$ ; RE  $27.6 \pm 9.2 \text{ pmol} \cdot \text{L}^{-1}$ ;  $p = 0.809$ )  
 14 concentrations were similar between HYPO and RE. Hydration status did not alter the serum  
 15 glucose ( $p = 0.627$ ) or insulin ( $p = 0.200$ ) responses during the OGTT. Muscle water content  
 16 was lower pre-OGTT after HYPO compared to RE ( $761 \pm 13 \text{ g} \cdot \text{kg}^{-1}$  wet weight *versus*  $772 \pm 18$   
 17  $\text{g} \cdot \text{kg}^{-1}$  RE), but similar post-OGTT (HYPO  $779 \pm 15 \text{ g} \cdot \text{kg}^{-1}$  *versus* RE  $780 \pm 20 \text{ g} \cdot \text{kg}^{-1}$ ; time  
 18  $p = 0.011$ ; trial\*time  $p = 0.055$ ). Resting energy expenditure was similar between hydration  
 19 states (stable between  $-1.21$  and  $5.94 \text{ kJ} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ ; trial  $p = 0.904$ ). Overall, despite acute mild  
 20 hypohydration increasing plasma copeptin concentrations and decreasing fasted cell volume  
 21 and muscle water, we found no effect on glycemic regulation.

22

23 **New and Noteworthy**

24 We demonstrated for the first time that an acute bout of hypohydration does not impact blood  
25 sugar control in healthy adults. Physiological responses to mild hypohydration ( $< 2\%$  body  
26 mass loss) caused an elevation in copeptin concentrations similar to that seen in those with  
27 diabetes, as well as reducing cell volume by  $\sim 3\%$ ; both these changes had been hypothesized  
28 to cause a higher blood sugar response.

29

## 30 **Introduction**

31 Whilst it is well-established that several dietary factors are implicated in glycemic regulation,  
32 research into the effects of hydration status is lacking. Observationally, plain water intake is  
33 typically associated with better glycemic regulation (6, 7, 26) which suggests that this could  
34 represent an inexpensive and time-efficient health intervention. However, rather than  
35 demonstrating a causal relationship, such associations may reflect water intake being a marker  
36 of a generally healthy lifestyle encompassing higher fibre intake and physical activity (19).

37

38 Understanding how hydration status impacts glycemia has consequences for both clinical  
39 practice and research, whereby fasted glucose concentrations and oral glucose tolerance tests  
40 (OGTTs) are commonly used for diabetes diagnostics or to ascertain the efficacy of an  
41 intervention. Standardization of food and fluid intake prior to these measures is required to  
42 prevent confounding influences, yet hydration status is not uniformly controlled for, despite  
43 studies in adults with type 1 and 2 diabetes finding higher glycemic responses when  
44 participants were hypohydrated *versus* euhydrated (5, 18). One study has also shown a similar  
45 deterioration in fasting glucose in healthy adults when manipulating extracellular osmolality,  
46 which mimics some of the physiological effects of hypohydration (20). Yet, the effect of  
47 directly manipulating hydration status on glycemic control in healthy adults has, to our  
48 knowledge, never been investigated.

49

50 There are several causal mechanisms through which hydration status could influence  
51 glycemia (6). Briefly, hypohydration decreases cell volume which has been hypothesized to  
52 influence glucoregulation (16, 20). Serum osmolality and arginine vasopressin (AVP)  
53 concentrations concurrently increase, potentially stimulating hepatic glucose output via

54 V1aR-binding in the liver (21, 29), and/or via adrenocorticotrophic hormone (ACTH) and  
55 cortisol secretion. Accordingly, high plasma copeptin concentrations (a surrogate marker of  
56 AVP) concentrations ( $\geq 10.70 \text{ pmol}\cdot\text{L}^{-1}$  in males and  $\geq 6.47 \text{ pmol}\cdot\text{L}^{-1}$  in females) have been  
57 associated with worse cardiometabolic health outcomes compared to those with low copeptin  
58 concentrations ( $\leq 4.59 \text{ pmol}\cdot\text{L}^{-1}$  and  $\leq 2.71 \text{ pmol}\cdot\text{L}^{-1}$ , respectively) (10, 11).

59

60 Considering the implications for clinical practice, research, and public health, we conducted a  
61 pilot study (n=5) whereby ~12-h hypohydration (sauna plus fluid restriction) induced a higher  
62 glycemic response to an OGTT compared to sauna plus fluid replacement (8). Such findings  
63 warranted further exploration in a tightly controlled study. Therefore we aimed to investigate  
64 the role of hydration status in glycemic regulation as well as examine key mechanisms  
65 (change in cell volume and AVP secretion), hypothesizing that compared to rehydration,  
66 hypohydration would cause a higher glycemic response to an OGTT.

## 67 **Methods**

### 68 Participants

69 Sixteen healthy adults volunteered to participate ( $n = 8$  males), with a mean ( $\pm$  standard  
 70 deviation; *SD*) age of  $30 \pm 9$  y, body mass of  $71.7 \pm 9.6$  kg, and body mass index of  
 71  $24.0 \pm 3.4$  kg·m<sup>-2</sup>. Participants were randomized using simple randomization (no strata) by  
 72 HAC upon consent using a random number generator (Excel 2013, Microsoft Corp, US).  
 73 Exclusion criteria were: aged  $< 18$  y or  $\geq 60$  y, metabolic disease (no body mass restrictions,  
 74 except self-reported weight loss  $> 5$  kg in previous 6 mo), drug dependency, or  
 75 pregnant/breastfeeding; thus all participants were considered healthy and not taking  
 76 medication or necessary supplements (except contraceptives). Females not taking continuous  
 77 hormonal contraceptives were tested during their estimated follicular phase (3-10 days after  
 78 onset of menses). Data were collected in South West England between June 2016 and January  
 79 2017, inclusive.

80

81 The sample size estimate was based on our pilot project in five participants (8) showing the  
 82 largest magnitude of effect at 45 minutes post-glucose ingestion ( $D = 1.1$  mmol·L<sup>-1</sup>). The  
 83 standard deviation at this time point in the control (rehydration) group was also 1.1 mmol·L<sup>-1</sup>,  
 84 resulting in an effect size ( $dz$ ) of 1. To provide a 95 % power (beta) to detect this effect at an  
 85 alpha ( $p$ ) of  $\leq 0.05$  using a two-tailed paired t-test required 16 participants.

86

### 87 Experimental design

88 This was a randomized crossover trial, with 5-35 d washout to account for the menstrual cycle  
 89 where applicable. Each trial arm consisted of three days of between-trial physical activity and  
 90 diet replication ('pre-trial monitoring phase'), a within-participant standardized 'intervention

day', and a full 'laboratory testing day' (as detailed below and in **Figure 1**; trial registration can be found Clinicaltrials.gov: NCT02841449 and Open Science Framework: [osf.io/ptq7msee](https://osf.io/ptq7msee); deviations to registered protocol are explained in full in the published dataset). The research received ethical approval from the NHS Health Research Authority Frenchay (ref: 16/SW/0057) and was conducted in accordance with the Declaration of Helsinki.

#### *Pre-trial monitoring phase*

Three days pre-trial, participants were asked to replicate their food/fluid intake (weighed food and fluid intake diaries; analysed using Nutritics Nutrition Analysis Software, Nutritics LTD, Dublin) and physical activity (combined heart rate and accelerometry; ActiHeart™; CamNtech, Cambridge, England), morning body mass (Inner scan; body composition monitor, model BC-543, TANITA corp. Japan) and urine specific gravity (**Table 1**). On the third monitoring day, participants were instructed to limit activity and to consume  $\geq 40$  ml·kg<sup>-1</sup> lean body mass (assessed via bioelectrical impedance) of non-alcoholic fluid to ensure euhydration before starting the intervention. This is in line with previous research aiming to achieve euhydration (9, 22). No restrictions on caffeinated beverages were placed during this phase, though it was emphasised to participants that they would need to replicate their fluid intake in the subsequent trial arm.

Diet diaries were analysed by the same coder within-participant, and the accuracy was verified by the lead author. Coding discrepancies were shared between all diet analysts to help ensure consistency between-participants. Nutrient intakes for each day of diet recording were taken from the software, and an average created for each participant. Physical activity energy



expenditure was analysed using ActiHeart 4 software which utilises a two-branch equation to estimate physical activity energy expenditure based on heart rate and accelerometry. Each ActiHeart™ was calibrated against measured resting metabolic rate for each participant and energy expenditure calculated using the ‘Group Cal JAP 2007’ model. Physical activity energy expenditure for each day was then averaged for each participant.

## Experimental protocol

### *Intervention day*

After the pre-trial monitoring phase, participants came to the laboratory between 0600-1000 h in a euhydrated state, following overnight fluid and food abstention from 2200 h the previous day. A peripheral quantitative computer tomography (pQCT; Stratec, Pforzheim, Germany) scan of a cross-section of the midpoint of their right thigh was taken as a proxy for muscle cell volume, after which a 10 ml euhydrated baseline blood sample was taken from an antecubital vein. Blood analytes from this venepuncture further confirmed compliance to the pre-trial monitoring phase, showing that participants were in a similar metabolic state before starting each trial arm (**Table 2**).

Participants then sat in a heat-tent (HYPO  $45.2 \pm 1.6^{\circ}\text{C}$ , RE  $44.6 \pm 1.3^{\circ}\text{C}$ ;  $p = 0.292$ ) wearing a sweat suit (RDX EVA Nylon Sauna Sweat Suit) for 60 min. Participants were nude weighed three times (Seca 803, Seca, Birmingham, UK) immediately before and after the heat-tent to determine body water losses. Post-heat-tent, participants were provided with a sandwich containing  $\geq 1$  g salt (Co-Operative Group Limited, UK) of their choosing (standardized within-participant; sandwiches contained  $1.5 \pm 0.5$  g, range 1.1-2.4 g) in order to maximise fluid retention and serum osmolality changes(17), and either  $3 \text{ mL}\cdot\text{kg}^{-1}$  body mass (HYPO),

or 40 mL·kg<sup>-1</sup> lean body mass plus 150% sweat losses (RE) of plain water to replace losses and account for the increased drink-induced diuresis (12). All other fluids were prohibited, including those containing caffeine and alcohol. Participants were only allowed to eat from a list of low-water-content foods (e.g. pizza, biscuits, nuts; avoiding fruit, vegetables, soups and other fluids). Physical activity energy expenditure and nutrient intake profiles were similar during the intervention day (all measured nutrients  $p \geq 0.102$ ), except water intake (HYPO  $0.52 \pm 0.11$  L·d<sup>-1</sup> *versus* RE  $3.7 \pm 0.8$  L·d<sup>-1</sup>;  $p < 0.001$ ), confirming compliance to the protocol.

#### *Laboratory testing day*

Participants arrived at the laboratory between 0700-0730 h after overnight food and fluid abstention from at least 2200 h the previous day, provided a urine sample and had their body mass recorded (Inner scan; body composition monitor, model BC-543, TANITA corp. Japan). A second pQCT scan of the midpoint of the right thigh was taken, after which participants were asked to rest semi-supine for 10-15 min. Their resting metabolic rate was recorded via indirect calorimetry from gaseous exchange (13), whereby 2 x 5 min measures were taken. Expired gas samples were collected in a Douglas bag (Hans Rudolph, Kansas City, USA) through falconia tubing (Baxter, Woodhouse and Taylor Ltd, Macclesfield, UK). Inspired air was simultaneously measured to adjust for ambient O<sub>2</sub> and CO<sub>2</sub> concentrations (4). Inspired and expired O<sub>2</sub> and CO<sub>2</sub> concentrations were measured using paramagnetic and infrared analysers (Mini HF 5200, Servomex Group Ltd., Sussex, UK). For metabolic rate data,  $n = 14$  as two participants were excluded from all metabolic rate and respiratory exchange ratio analyses due to fasted values  $> 1$ , which appeared to be caused by hyperventilation at these time points. In a subgroup of participants ( $n = 9$ ) an additional 5 min Douglas bag was taken

at 25-30 min post-glucose ingestion to establish whether the initial diet induced thermogenesis trend was linear between 0 and 60 min.

Participants then placed their hand in a hotbox (Medical Engineering Unit, University of Nottingham, UK) set to 55°C for five minutes before an indwelling cannula was fitted in an antecubital vein and a fasted blood sample was drawn. An opt-in muscle biopsy was taken (n = 9), followed by a second fasted blood sample in order to quantify any changes from the expected stress response of the biopsy. The muscle samples were acquired via a ~3 mm incision at the anterior aspect of the thigh under local anaesthetic (Lidocaine 1 %, without adrenaline; Hameln Pharmaceuticals Ltd, Brockworth, UK) from the *vastus lateralis* by percutaneous needle biopsy technique (3). Samples were immediately removed from the needle and snap frozen in liquid nitrogen before storage at -80°C.

A 75 g OGTT (Polycal, Nutricia, England) was subsequently conducted. Arterialized-venous blood samples (10 ml) were drawn at 15 min intervals for 120 min. Expired gas samples (1 x 5 min Douglas bag as described previously) were collected hourly. A second muscle biopsy was then taken (for those who had opted-in; n = 7) after 120 min.

#### Muscle water content analysis

Total muscle water content was determined by weighing the biopsy samples before and after freeze drying (23). Samples were weighed on a high precision (resolution 0.01 mg) electronic balance (Mettler Toledo AE240) whilst frozen (wet weight). The time elapsed between sample removal from storage and weighing was fixed and recorded to allow for standardization of tissue water evaporation. Samples were then freeze dried using a LyoDry

Compact, MechaTech Systems freeze dryer for 24 h at -55°C before being weighed again (dry weight) using the same precision balance. Total muscle water content was calculated as grams of water per kilogram of wet muscle using the following equation:  $(\text{wet weight} - \text{dry weight} / \text{wet weight}) * 1000$ .

#### Biochemical analysis

Six millilitres of blood was decanted into two EDTA tubes and spun for 10 min at 2500-3446 x g at 4°C. The remaining four millilitres of blood were decanted into a serum tube, left for at least 30 min at room temperature and then spun as per the plasma. The plasma and serum were aliquoted into separate Eppendorf tubes and frozen at -20°C before being moved to a -80°C freezer for longer term storage.

Metabolites and hormones were measured using commercially available ELISAs (plasma arginine<sup>8</sup> vasopressin, Enzo Life Sciences; serum insulin, Mercodia), ECLIAS (plasma ACTH, Roche), ECLIs (plasma cortisol, Roche), automated immune analyzers (plasma copeptin, ThermoFisher Kryptor Compact Plus) and spectrophotometric assays (serum glucose, RX Daytona, Randox Laboratories). Osmolality was measured using freezing-point depression (serum osmolality, Gonotec Osmomat auto; urine osmolality, Micro-Osmometer 3300) and urine specific gravity was measured using a handheld refractometer (SUR-NE Clinical Refractometer, Atago, Japan).

#### Statistical analysis

The primary aim of the study was the glycemic response to an OGTT. Secondary outcomes were to investigate the insulin, vasopressin (copeptin), rested energy expenditure, and

substrate utilization responses to the OGTT, and the change in urine osmolality, urine specific gravity, cell volume, serum osmolality and muscle water content from the intervention. We were additionally able to investigate ACTH and cortisol.

Data were analyzed using paired samples *t*-test or 2-way repeated measures (trial, time, trial\*time) analysis of variance or appropriate non-parametric tests (SPSS, version 22, IBM). Normality was checked visually via P-P plots, histograms of standardized residuals, and scatterplots of the standardized predicted *versus* residual values. Asphericity was determined using Greenhouse-Geisser epsilon; values < 0.75 were corrected for using Greenhouse Geisser correction and values > 0.75 used Huynh-Feldt correction. Total area under the curve (AUC) and incremental AUC (iAUC) were calculated as per Wolever(30). Analyses were repeated excluding those who had muscle biopsies to explore whether their inclusion skewed the overall findings. All analyses were two-tailed with an alpha level of  $\leq 0.05$ .

## Results

Markers of hydration status (body mass, urine specific gravity, urine osmolality, and cross-sectional muscle area) suggested compliance to both the HYPO and RE protocol (**Table 3**).

### *Serum glucose concentration*

Fasting serum glucose concentrations were similar between HYPO ( $5.10 \pm 0.42 \text{ mmol}\cdot\text{L}^{-1}$ ) and RE ( $5.02 \pm 0.40 \text{ mmol}\cdot\text{L}^{-1}$ ;  $p = 0.327$ ). There were no differences in the glycemic response between HYPO and RE during the OGTT (trial  $F = 0.246$ ,  $p = 0.627$ ; time  $F = 41.128$ ,  $p < 0.001$ ; trial\*time  $F = 0.944$ ,  $p = 0.430$ ; **Figure 2a**). No differences were found in the serum glucose iAUC (HYPO  $303 \pm 121 \text{ mmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ , RE  $306 \pm 113 \text{ mmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ ,  $p = 0.866$ ), AUC (HYPO  $926 \pm 169 \text{ mmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ , RE  $934 \pm 120 \text{ mmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ ,  $p = 0.819$ ), or time to peak (HYPO  $46 \pm 14 \text{ min}$ , RE  $48 \pm 14 \text{ min}$ ,  $p = 0.609$ ).

### *Serum insulin concentration*

Serum insulin concentrations were similar in the fasted state (HYPO  $27.09 \pm 9.66 \text{ pmol}\cdot\text{L}^{-1}$ , RE  $27.62 \pm 9.21 \text{ pmol}\cdot\text{L}^{-1}$ ;  $p = 0.809$ ). During the OGTT, there were no differences between HYPO and RE in the insulinemic response (trial  $F = 1.800$ ,  $p = 0.200$ ; time  $F = 29.597$ ,  $p < 0.001$ ; trial\*time  $F = 0.232$ ,  $p = 0.859$ ; **Figure 2b**). There were no differences in the iAUC (HYPO  $20860 \pm 8311$ , RE  $21937 \pm 8340 \text{ pmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ ,  $p = 0.369$ ), AUC (HYPO  $23958 \pm 9275 \text{ pmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ , RE  $25326 \pm 8679 \text{ pmol}\cdot 120 \text{ min}\cdot\text{L}^{-1}$ ,  $p = 0.359$ ), or time to peak (HYPO  $54 \pm 25 \text{ min}$ , RE  $58 \pm 26 \text{ min}$ ,  $p = 0.633$ ) serum insulin concentrations.

### 248 *Serum osmolality*

249 There was an increase from baseline in serum osmolality during HYPO of  $9 \pm 6 \text{ mOsm} \cdot \text{kg}^{-1}$   
 250 with relative stability from baseline during RE ( $\Delta 1 \pm 4 \text{ mOsm} \cdot \text{kg}^{-1}$ ; HYPO vs RE  $p < 0.001$ ;  
 251 Table 3). Similar differences remained throughout the OGTT (trial  $F = 74.457$ ,  $p < 0.001$ ),  
 252 reflected in a greater AUC during HYPO compared to RE (HYPO  $35355 \pm$   
 253  $692 \text{ mOsm} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ , RE  $34232 \pm 701 \text{ mOsm} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ ,  $p < 0.001$ ).

254

### 255 *Plasma copeptin concentration*

256 Due to the difficulties in measuring AVP(24), our data were unreliable, but are available in  
 257 the published dataset. Plasma copeptin was measured as a reliable marker of AVP  
 258 secretion(24). Fasted (pre-biopsy) plasma copeptin concentrations increased significantly  
 259 from baseline after HYPO ( $\Delta 14.32 \pm 9.32$ ;  $p < 0.001$ ) but not after RE ( $\Delta 0.46 \pm 2.34$ ;  $p =$   
 260  $0.457$ ). Plasma copeptin concentrations were consistently higher throughout the OGTT during  
 261 HYPO compared to RE (trial  $F = 14.193$ ,  $p = 0.002$ ; time  $F = 1.285$ ,  $p = 0.282$ ; trial\*time  $F =$   
 262  $1.396$ ,  $p = 0.261$ ; **Figure 3a**), confirmed by a higher AUC (HYPO  $2704 \pm 2398 \text{ pmol} \cdot 120$   
 263  $\text{min} \cdot \text{L}^{-1}$ , RE  $961 \pm 1488 \text{ pmol} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ ,  $p = 0.001$ ).

264

### 265 *Plasma adrenocorticotrophic hormone concentration (ACTH)*

266 There were no differences in the ACTH response between HYPO and RE (trial  $F = 2.541$ ,  
 267  $p = 0.132$ ; time  $F = 6.120$ ,  $p = 0.025$ ; trial\*time  $F = 1.343$ ,  $p = 0.266$ ) during the OGTT, nor  
 268 were there differences in the AUC (HYPO  $405 \pm 195 \text{ pmol} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ , RE  
 269  $468 \pm 255 \text{ nmol} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ ,  $p = 0.121$ ).

270

271 *Plasma cortisol concentration*

272 Plasma cortisol concentrations were similar between HYPO and RE (trial  $F = 0.216$ ,  
 273  $p = 0.649$ ; time  $F = 19.416$ ,  $p < 0.001$ ; trial\*time  $F = 0.275$ ,  $p = 0.674$ ), with no differences in  
 274 the plasma cortisol AUC (HYPO  $35445 \pm 17432 \text{ nmol} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ , RE  $36716 \pm 24915$   
 275  $\text{nmol} \cdot 120 \text{ min} \cdot \text{L}^{-1}$ ,  $p = 0.642$ ).

276

277 *Cross-sectional muscle area*

278 Cross-sectional muscle area as a proxy for muscle cell volume reduced significantly from  
 279 baseline after HYPO ( $\Delta -2.9 \pm 2.7 \%$ ;  $p = 0.003$ ) but not after RE ( $\Delta 0.0 \pm 2.1 \%$ ;  $p = 0.936$ ;  
 280 Table 3).

281

282 *Muscle water content*

283 Pre-OGTT muscle biopsies showed that muscle water content was lower during HYPO  
 284 ( $760.5 \pm 13.2 \text{ g} \cdot \text{kg}^{-1}$ ) compared to RE ( $771.6 \pm 17.8 \text{ g} \cdot \text{kg}^{-1}$ ) but this difference dissipated post-  
 285 OGTT (HYPO  $778.6 \pm 15.1 \text{ g} \cdot \text{kg}^{-1}$ , RE  $780.2 \pm 20.0 \text{ g} \cdot \text{kg}^{-1}$ ; trial  $F = 3.183$ ,  $p = 0.135$ ; time  
 286  $F = 15.36$ ,  $p = 0.011$ ; trial\*time  $F = 6.265$ ,  $p = 0.055$ ; **Figure 4**).

287

288 *Resting energy expenditure*

289 Resting metabolic rate was similar between trial arms in the fasted (HYPO  
 290  $96.32 \pm 11.94 \text{ kJ} \cdot \text{d}^{-1} \cdot \text{min}^{-1}$ , RE  $95.11 \pm 13.09 \text{ kJ} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ ,  $p = 0.400$ ) and postprandial (trial  $F =$   
 291  $0.015$ ,  $p = 0.904$ ; time  $F = 10.130$ ,  $p = 0.001$ ; trial\*time  $F = 0.140$ ,  $p = 0.798$ ) state.  
 292 Participants had similar fasting respiratory exchange ratios (HYPO  $0.84 \pm 0.05$ , RE



0.84  $\pm$  0.06;  $p = 0.900$ ), although carbohydrate oxidation post-glucose ingestion had a tendency to increase to a greater extent in the RE trial at 60 (HYPO 0.88 $\pm$ 0.04, RE 0.93 $\pm$ 0.09) and 120 min (HYPO 0.87  $\pm$  0.07, RE 0.91  $\pm$  0.07; trial  $F = 3.650$ ,  $p = 0.078$ ; time  $F = 14.693$ ,  $p < 0.001$ ; trial\*time  $F = 3.754$ ,  $p = 0.039$ ).

### *Plasma volume*

Due to an error in postural control during the baseline (euhydrated) venepuncture, the plasma volume data were invalid. We have included details of how plasma volume was measured and the data obtained in the published dataset.

### *Sensitivity analysis*

Those who had muscle biopsies demonstrated a distinct stress response in their plasma copeptin (**Figure 3b**), ACTH and cortisol concentrations (shown below). Removing those who had any biopsies did not alter the findings.

#### Copeptin

Removing those who had any biopsies did not meaningfully effect the trend in plasma copeptin concentration throughout the OGTT ( $n = 7$ : trial  $F = 13.517$ ,  $p = 0.010$ ; time  $F = 4.081$ ,  $p = 0.040$ ; trial\*time  $F = 1.489$ ,  $p = 0.262$ ), though the overall AUC was lower ( $n = 7$ : HYPO 11916  $\pm$  1661 pmol\*120 min·L<sup>-1</sup>, RE 390  $\pm$  177 pmol\*120 min·L<sup>-1</sup>,  $p = 0.028$ ).

#### ACTH

Removing those who had opted-in for muscle biopsies eliminated the time effect and highlighted a small though non-significant trend towards higher ACTH concentrations during RE compared to HYPO ( $n = 7$ : trial  $F = 4.203$ ,  $p = 0.086$ ; time  $F = 0.989$ ,  $p = 0.361$ ;

trial\*time  $F = 1.729$ ,  $p = 0.219$ ). When biopsy participants were removed, the AUCs were lower ( $n = 7$ : HYPO  $292 \pm 139$  pmol\*120·L<sup>-1</sup>, RE  $355 \pm 86$  pmol\*120·L<sup>-1</sup>,  $p = 0.176$ ) but there was still no difference between HYPO and RE.

### Cortisol

In accordance with the plasma copeptin and ACTH response, plasma cortisol concentration also increased post-biopsy. Removing these participants did not meaningfully alter the results, though the time effect was no longer evident ( $n = 7$ : trial  $F = 0.278$ ,  $p = 0.617$ ; time  $F = 5.172$ ,  $p = 0.055$ ; trial\*time  $F = 0.260$ ,  $p = 0.686$ ). Despite a post-biopsy peak in plasma cortisol concentration, the AUC was higher when the biopsy participants were removed ( $n = 7$ : HYPO  $37920 \pm 25008$  nmol\*120·L<sup>-1</sup>, RE  $40989 \pm 37507$  nmol\*120·L<sup>-1</sup>,  $p = 0.735$ ), with no difference between HYPO and RE.

### Resting metabolic rate

In the subgroup who had the additional measure at 30 min post-glucose ingestion ( $n = 9$ ), no difference in RMR (trial  $F = 0.346$ ,  $p = 0.573$ ; time  $F = 6.087$ ,  $p = 0.009$ ; trial\*time  $F = 0.586$ ,  $p = 0.508$ ) or RER (trial  $F = 0.433$ ,  $p = 0.529$ ; time  $F = 17.330$ ,  $p < 0.001$ ; trial\*time  $F = 0.467$ ,  $p = 0.607$ ) was apparent according to hydration status.

## Discussion

This randomized crossover trial is the first to show that neither fasted nor postprandial glycemia or insulinemia are influenced by hydration status in healthy adults, contrary to our hypothesis. The key implication of this work is that clinicians and researchers may not have to control for hydration status when investigating glycemic regulation in healthy adults.

Participants replicated their diet and activity four days pre-trial, reducing known confounding influences. Average body mass loss during HYPO was 1.9 % which is within the typical range to induce thirst and is not uncommon in the general population (2), increasing the external validity of these findings. In the hypohydrated state, copeptin (a surrogate marker of AVP) concentrations increased from levels seen in healthy adults to levels reported in those at highest risk of metabolic syndrome (10), with an accompanying reduction in muscle cell volume of ~3 %, hypothesized to be detrimental to glycemic regulation (16). Therefore the level of hypohydration achieved was sufficient to induce physiological changes that theoretically have meaningful health implications; such changes did not occur when participants were rehydrated.

Despite these physiological changes hypothesized to cause higher glycemia, fasted and postprandial glycemia was similar between HYPO and RE. These results are in contrast to similar work in those with diabetes (5, 18). In both previous studies, participants were required to withdraw from diabetes medication; accordingly Burge *et al.* (5) found higher glucosuria when euhydrated compared to hypohydrated potentially explaining the lower glycemic response. As this effect of glucosuria has previously been alluded to (31), it is a possible (at least partial) explanation for the findings of Johnson *et al.* (18). This hypothesis could be tested by comparing glycemic regulation in those with diabetes during medication

withdrawal *versus* prescription. Glucosuria should not occur in healthy adults, potentially explaining why we did not find a lower glycemia during RE compared to HYPO.

Similarly, our findings conflict with research in healthy adults. Keller *et al.* (20) administered intravenous saline and/or desmopressin to induce changes specifically in extra-cellular osmolality, finding higher fasted glucose concentrations during hyperosmolality. This method of dehydration however is not representative of whole body water losses, potentially explaining the discordance between our findings. The present study also contradicts our own pilot work (8), most likely because of the lack of rigorous pre-trial standardization of diet (verbal 24-h recall), physical activity (self-reported replication), and hydration status (no pre-intervention measures) in the pilot.

A key mechanism by which elevations in AVP induce poor glycemic control is through the hypothalamic-pituitary-adrenal (HPA) axis, stimulating ACTH and cortisol secretion. Despite the increase we observed in plasma copeptin concentrations, plasma ACTH and cortisol concentrations were not different between HYPO and RE suggesting that in healthy adults, short-term hypohydration is not a sufficient stimulus to induce a stress response along the HPA axis. This theory is in accordance with earlier work highlighting that the role of AVP in ACTH secretion is predominantly a response to physical stress (15). Nevertheless, we did not find a difference in ACTH or cortisol by hydration status in those who had the muscle biopsies, despite higher copeptin responses during HYPO. In previous work in those with type 2 diabetes, cortisol concentrations did increase 45 min post-glucose ingestion when hypohydrated (18), perhaps suggesting an interaction between hydration status and feeding in

those with metabolic impairments. However, as copeptin did not increase postprandially in our study, the mechanism for this cortisol response is unlikely to be AVP-mediated.

Another mechanism proposed to link hypohydration to higher glycemia is changes to cell volume influencing insulin and glucagon secretion, though a limitation of our study is that glucagon was not measured. Muscle cell volume reduced by ~3 % from baseline, compared to no change when participants were rehydrated—a reduction that may deteriorate glucose tolerance (16, 20). The pQCT data were confirmed by the muscle biopsy samples which showed lower pre-OGTT total muscle water content in HYPO *versus* RE. Interestingly post-OGTT the muscle water content difference diminished suggesting the introduction of glucose to the cell created a strong enough stimulus to move water from other compartments into skeletal muscle. Conversely, muscle water content did not change pre- to post-OGTT during RE, perhaps showing greater overall water balance as no extra water was needed intracellularly for glycogen storage (25).

Hydration status could influence metabolic health over longer time periods by altering thermogenesis. Whilst it has been shown, albeit inconsistently, that water ingestion induces greater thermogenesis (27), our study did not support these findings, supporting evidence that the thermogenic effect is from consuming (cold) water rather than altering hydration status (27). There was a tendency for higher carbohydrate utilization during RE compared to HYPO, perhaps indicating greater hepatic glucose output during RE to account for the higher carbohydrate utilization; however these findings should be interpreted cautiously as the study was not powered for these outcomes.

There are several other speculative theories that could explain our null findings which we did not test. Firstly, it could be that healthy adults have a greater capacity to handle metabolic challenges such as acute bouts of hypohydration, and whilst physiological changes occur to handle this flux, such deviations ensure maintenance of homeostasis and therefore minimize metabolic disruption. Accordingly, both serum osmolality and plasma copeptin concentrations increased during HYPO *versus* RE, suggesting higher AVP secretion to help maintain homeostasis. Considering the level of HYPO we induced is not uncommon in the population (2) and caused an increase in copeptin concentrations associated with poor cardiometabolic health (10, 11), it may be that such commonly achieved levels of hypohydration have detrimental longer terms health effects not captured by our acute study design.

A further hypothesis is that the conflicting roles of vasopressin receptors (VR) in adipose tissue insulin sensitivity led to a null effect on glucose tolerance during HYPO. Specifically, V1aR<sup>-/-</sup> mice have reduced adipose tissue glucose tolerance, whereas V1bR<sup>-/-</sup> mice have increased adipose tissue insulin sensitivity (1, 14, 28). If these findings translate into humans (and assuming a similar propensity for VR binding), this could mean that HYPO-induced AVP secretion, such as that achieved in our study, leads to AVP binding on both V1aR and V1bR resulting in net zero effect on glycemic regulation. However, the present study was not equipped to examine this speculative theory.

Overall, despite physiologically and clinically meaningful increases in plasma copeptin and serum osmolality, and a notable reduction in cell volume supporting a systemic difference in hydration status between trial arms, we demonstrated for the first time that acute hypohydration did not alter the glycemic response. Our findings suggest that when conducting

OGTTs in healthy adults, hydration status may not necessarily need to be strictly controlled for. Although longer-term research is needed to understand the glucoregulatory effects of chronic hypohydration, these data suggest that acute manipulations of hydration status in healthy adults do not impact fasted or postprandial glycemic regulation.

#### **Acknowledgements**

We would like to thank Dr Oliver Perkin for his invaluable technical help with the pQCT scanner and interpreting these results. Neither funding source had any role in the study design, data analysis, or writing or publishing of this article.

#### **Grants**

This work was supported by the Economic and Social Research Council (grant no.: ES/J50015X/1) and the European Hydration Institute Graduate Research Grant.

#### **Disclosures**

This work was supported by the European Hydration Institute Graduate Research Grant. HAC has accepted conference fees from Danone. OM has received consultancy honoraria from Danone Research. LJJ has previously received funding for hydration-related research from PepsiCo Inc., the European Hydration Institute and Volac International Ltd and has performed consultancy work for Lucozade Ribena Suntory. LJ has received funding from Kellogg Europe and Danone Baby Nutrition. JAB has received funding from LucozadeRibenaSuntory, PepsiCo, and Kenniscentrum Suiker. No other authors declared a conflict of interest.

## References

1. **Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, and Tanoue A.** Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. *Endocrinology* 148: 2075-2084, 2007.
2. **Armstrong LE.** Hydration Biomarkers During Daily Life. *Nutrition Today* 47: S3-S6, 2012.
3. **Bergström J.** Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. *Scandinavian Journal of Clinical and Laboratory Investigation* 35: 606-616, 1975.
4. **Betts JA, and Thompson D.** Thinking outside the bag (not necessarily outside the lab). *Medicine and Science in Sports and Exercise* 44: 2040, 2012.
5. **Burge MR, Garcia N, Qualls CR, and Schade DS.** Differential effects of fasting and dehydration in the pathogenesis of diabetic ketoacidosis. *Metabolism: clinical and experimental* 50: 171-177, 2001.
6. **Carroll HA, Betts JA, and Johnson L.** An investigation into the relationship between plain water intake and glycated Hb (HbA1c): a sex-stratified, cross-sectional analysis of the UK National Diet and Nutrition Survey (2008-2012). *British Journal of Nutrition* 116: 1770-1780, 2016.
7. **Carroll HA, Davis MG, and Papadaki A.** Higher plain water intake is associated with lower type 2 diabetes risk: a cross-sectional study in humans. *Nutrition research* 35: 865-872, 2015.
8. **Carroll HA, Johnson L, and Betts JA.** Effect of hydration status on glycemic control: A pilot study. In: *American College of Sports Medicine*. Boston, MA.: 2016.
9. **Corney RA, Horina A, Sunderland C, and James LJ.** Effect of hydration status and fluid availability on ad-libitum energy intake of a semi-solid breakfast. *Appetite* 91: 399-404, 2015.
10. **Enhörning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, and Melander O.** Plasma copeptin, a unifying factor behind the metabolic syndrome. *The Journal of clinical endocrinology and metabolism* 96: E1065-1072, 2011.
11. **Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, and Melander O.** Plasma copeptin and the risk of diabetes mellitus. *Circulation* 121: 2102-2108, 2010.
12. **Evans GH, James LJ, Shirreffs SM, and Maughan RJ.** Optimizing the restoration and maintenance of fluid balance after exercise-induced dehydration. *J Appl Physiol (1985)* 122: 945-951, 2017.
13. **Frayn KN.** Calculation of substrate oxidation rates in vivo from gaseous exchange. *Journal of Applied Physiology* 55: 628-634, 1983.
14. **Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, Tsujimoto G, and Tanoue A.** Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. *The Journal of physiology* 584: 235-244, 2007.
15. **Gibbs DM.** Vasopressin and oxytocin: hypothalamic modulators of the stress response: a review. *Psychoneuroendocrinology* 11: 131-139, 1986.
16. **Haussinger D, Lang F, and Gerok W.** Regulation of cell function by the cellular hydration state. *Am J Physiol* 267: E343-355, 1994.
17. **James LJ, and Shirreffs SM.** Fluid and electrolyte balance during 24-hour fluid and/or energy restriction. *International Journal of Sport Nutrition and Exercise Metabolism* 23: 545-553, 2013.



18. **Johnson EC, Bardis CN, Jansen LT, Adams JD, Kirkland TW, and Kavouras SA.** Reduced water intake deteriorates glucose regulation in patients with type 2 diabetes. *Nutrition research* 43: 25-32, 2017.
19. **Kant AK, Graubard BI, and Atchison EA.** Intakes of plain water, moisture in foods and beverages, and total water in the adult US population--nutritional, meal pattern, and body weight correlates: National Health and Nutrition Examination Surveys 1999-2006. *The American journal of clinical nutrition* 90: 655-663, 2009.
20. **Keller U, Szinnai G, Bilz S, and Berneis K.** Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. *European journal of clinical nutrition* 57 Suppl 2: S69-74, 2003.
21. **Keppens S, and de Wulf H.** The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. *Biochim Biophys Acta* 588: 63-69, 1979.
22. **Minshull C, and James L.** The effects of hypohydration and fatigue on neuromuscular activation performance. *Appl Physiol Nutr Metab* 38: 21-26, 2013.
23. **Mora-Rodriguez R, Sanchez-Roncero A, Fernandez-Elias VE, Guadalupe-Grau A, Ortega JF, Dela F, and Helge JW.** Aerobic Exercise Training Increases Muscle Water Content in Obese Middle-Age Men. *Medicine and science in sports and exercise* 48: 822-828, 2016.
24. **Morgenthaler NG, Struck J, Jochberger S, and Dunser MW.** Copeptin: clinical use of a new biomarker. *Trends in endocrinology and metabolism: TEM* 19: 43-49, 2008.
25. **Olsson KE, and Saltin B.** Variation in total body water with muscle glycogen changes in man. *Acta Physiol Scand* 80: 11-18, 1970.
26. **Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L, and Group DESIRS.** Low water intake and risk for new-onset hyperglycemia. *Diabetes care* 34: 2551-2554, 2011.
27. **Stookey JJ.** Negative, Null and Beneficial Effects of Drinking Water on Energy Intake, Energy Expenditure, Fat Oxidation and Weight Change in Randomized Trials: A Qualitative Review. *Nutrients* 8: 2016.
28. **Tanoue A.** New Topics in Vasopressin Receptors and Approach to Novel Drugs: Effects of Vasopressin Receptor on Regulations of Hormone Secretion and Metabolisms of Glucose, Fat, and Protein. *Journal of Pharmacological Sciences* 109: 50-52, 2009.
29. **Whitton PD, Rodrigues LM, and Hems DA.** Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. *Biochem J* 176: 893-898, 1978.
30. **Wolever TM.** Effect of blood sampling schedule and method of calculating the area under the curve on validity and precision of glycaemic index values. *The British journal of nutrition* 91: 295-300, 2004.
31. **Zerbe RL, Vinicor F, and Robertson GL.** Plasma vasopressin in uncontrolled diabetes mellitus. *Diabetes* 28: 503-508, 1979.

## Figure legends

Figure 1. Protocol schematic. \*muscle biopsies were taken only in those who opted in.

\*\*RMR at 30 min taken in subsample ( $n = 9$ ). Abbreviations: OGTT, oral glucose tolerance test; pQCT, peripheral quantitative computer tomography scan; RMR, resting metabolic rate

Figure 2. (a) Serum glucose (trial  $F = 0.246$ ,  $p = 0.627$ ; time  $F = 41.128$ ,  $p < 0.001$ ; trial\*time  $F = 0.944$ ,  $p = 0.430$ ) and (b) insulin (trial  $F = 1.800$ ,  $p = 0.200$ ; time  $F = 29.597$ ,  $p < 0.001$ ; trial\*time  $F = 0.232$ ,  $p = 0.859$ ) responses to a 75 g oral glucose tolerance test ( $n = 16$ ). Data are means and normalized 95% confidence intervals. Abbreviations: HYPO, hypohydrated trial arm; RE, rehydrated trial arm


Figure 3. (a) Plasma copeptin response during an oral glucose tolerance test ( $n = 16$ ; trial  $F = 14.193$ ,  $p = 0.002$ ; time  $F = 1.285$ ,  $p = 0.282$ ; trial\*time  $F = 1.396$ ,  $p = 0.261$ ). (b) Plasma copeptin response during an oral glucose tolerance test separating those who had muscle biopsies on both trials ( $n = 7$ ) to those who had no biopsies on neither trial ( $n = 7$ ). For those who had biopsies, a fasted blood sample was taken before the biopsy (time point 'Pre-biopsy') and after the biopsy immediately before the glucose was ingested (time point '0'), and for those who did not have the biopsies, only one fasted sample was taken (time point '0'). \* $p < 0.050$ , \*\* $p < 0.010$  comparing HYPO and RE (trial effect) after Bonferroni adjustment for multiple comparisons. Error bars: normalized 95% confidence intervals. Abbreviations: HYPO, hypohydrated trial arm; RE, rehydrated trial arm


Figure 4. Average (thick lines) and individual (thin lines) muscle water content pre-OGTT and post-OGTT during HYPO and RE ( $n = 6$ ; trial  $F = 3.183$ ,  $p = 0.135$ ; time  $F = 15.36$ ,  $p =$



572 0.011; trial\*time  $F = 6.265$ ,  $p = 0.055$ ). \* $p$ -value Bonferroni adjusted for multiple  
573 comparisons. Black lines are HYPO; grey lines are RE. Abbreviations: HYPO, hypohydrated  
574 trial arm; OGTT, oral glucose tolerance test; RE, rehydrated trial arm

575

576










Table 1: Mean  $\pm$  *SD* of lifestyle factors and markers of hydration status during the 3-day pre-trial monitoring phase (n = 16)

	Hypohydration	Rehydration	<i>p</i> -value <sup>1</sup>
	Mean $\pm$ <i>SD</i>	Mean $\pm$ <i>SD</i>	
Energy intake (kJ·day <sup>-1</sup> )	9777 $\pm$ 3765	10091 $\pm$ 3513	0.541
Carbohydrate (g·day <sup>-1</sup> )	274 $\pm$ 125	271 $\pm$ 125	0.829
Fat (g·day <sup>-1</sup> )	84 $\pm$ 51	93 $\pm$ 53	0.258
Protein (g·day <sup>-1</sup> )	105 $\pm$ 52	103 $\pm$ 41	0.729
Sodium (mg·day <sup>-1</sup> )	2487 $\pm$ 1774	2497 $\pm$ 1156	0.970
Potassium (mg·day <sup>-1</sup> )	3486 $\pm$ 3417	2778 $\pm$ 1347	0.128
Water (L·day <sup>-1</sup> food + fluid)	3.3 $\pm$ 1.5	3.2 $\pm$ 1.4	0.315
Physical activity energy expenditure (kJ·day <sup>-1</sup> )	4462 $\pm$ 2276	4314 $\pm$ 1764	0.381
Body mass (kg)	71.7 $\pm$ 9.6	71.8 $\pm$ 9.8	0.340
Body mass index (kg·m <sup>-2</sup> )	23.6 $\pm$ 4.2	23.2 $\pm$ 4.8	0.409
USG	1.018 $\pm$ 0.005	1.018 $\pm$ 0.005	0.932

<sup>1</sup> Statistical significance calculated using two-tailed paired *t*-test.

Abbreviations: *SD*, standard deviation; USG, urine specific gravity



Table 2: Overnight fasted concentrations of blood hormones and metabolites in a euhydrated state at baseline before each trial arm (n = 16)

	Pre-hypohydration	Pre-rehydration	<i>p</i> -value <sup>1</sup>
	Mean ± <i>SD</i>	Mean ± <i>SD</i>	
Plasma ACTH (pmol·L <sup>-1</sup> )	3.54 ± 1.98	3.61 ± 1.48	0.841
Plasma copeptin (pmol·L <sup>-1</sup> )	4.45 ± 2.01	4.25 ± 1.83	0.462
Plasma cortisol (nmol·L <sup>-1</sup> )	316 ± 162	330 ± 269	0.687
Serum glucose (mmol·L <sup>-1</sup> )	5.04 ± 0.30	4.98 ± 0.46	0.493
Serum insulin (pmol·L <sup>-1</sup> )	30.4 ± 11.3	29.8 ± 11.0	0.852
Serum osmolality (mOsm·kg <sup>-1</sup> )	287 ± 6	285 ± 4	0.152

<sup>1</sup> Statistical significance calculated using two-tailed paired *t*-test.

Abbreviations: ACTH, adrenocorticotrophic hormone; *SD*, standard deviation

Table 3: Mean  $\pm$  *SD* markers of hydration status between the morning of the intervention day (euhydrated state) and full laboratory testing day

	Hypohydration			Rehydration			$p_{\text{difference BL}}$ HYPO vs RE <sup>1</sup>	$p_{\text{difference FT}}$ HYPO vs RE <sup>1</sup>
	BL	FT	$\Delta$ BL to FT HYPO	BL	FT	$\Delta$ BL to FT RE		
	(Mean $\pm$ <i>SD</i> )	(Mean $\pm$ <i>SD</i> )	(95 % CI)	(Mean $\pm$ <i>SD</i> )	(Mean $\pm$ <i>SD</i> )	(95 % CI)		
Body mass (kg)	71.6 $\pm$ 9.8	70.3 $\pm$ 9.7	-1.3 (-1.8, -0.8)	71.5 $\pm$ 9.8	71.4 $\pm$ 9.9	-0.1 (-0.3, -0.1)	0.675	< 0.001
Body water (kg)	37.3 $\pm$ 7.0	36.8 $\pm$ 6.5	-0.4 (-0.8, 0.0)	37.6 $\pm$ 5.8	37.8 $\pm$ 5.3	0.1 (-0.3, 0.6)	0.669	0.226
CSMA (mm <sup>2</sup> )	12773 $\pm$ 2829	12408 $\pm$ 2662	-365 (-587, -138)	12682 $\pm$ 2684	12688 $\pm$ 2739	6 (-137, 148)	0.304	0.002
USG	1.017 $\pm$ 0.005	1.027 $\pm$ 0.003	0.010 (0.007, 0.014)	1.013 $\pm$ 0.005	1.016 $\pm$ 0.003	0.003 (0.000, 0.005)	0.017	< 0.001
Urine osmolality (mOsm·kg <sup>-1</sup> )	554 $\pm$ 185	965 $\pm$ 84	442 (355, 529)	419 $\pm$ 147	532 $\pm$ 126	93 (9, 178)	0.023	< 0.001

<sup>1</sup> Statistical significance calculated using paired *t*-test.

Abbreviations: BL, euhydrated baseline measure from the morning of the intervention day; CI, confidence interval; CSMA, cross-sectional muscle area; HYPO, hypohydrated trial arm; FT, full trial day; RE, rehydrated trial arm; *SD*, standard deviation; USG, urine specific gravity